Company profilePharmaceutical#167 of 1,318 in Pakistan2 DRAP alerts

NOVARTIS PHARMA (PAK) LTD

Pharmaceutical company · 105 brands · 109 molecules

Ranked #12 of 32 companies in Antiinflammatory Agents And Antiinfectives In Combination

105 registered products 63 pharmaceutical brands 109 distinct molecules 2 DRAP alerts

Company overview

105

registered products

pharmaceutical brands

109

distinct molecules

therapeutic classes

DRAP alerts

NOVARTIS PHARMA (PAK) LTD is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 105 product registrations across 109 distinct molecules. It is the 167th largest registrant in Pakistan by product count, and ranks 12th of 32 in Antiinflammatory Agents And Antiinfectives In Combination. Its portfolio is concentrated in Antiinflammatory Agents And Antiinfectives In Combination and Drugs For Treatment Of Bone Diseases. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by NOVARTIS

11 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antihistamines For Systemic Use 3

T-Day90MlRs 142.5 T-Day5MgRs 114 T-Day5mgRs 342

Other 8

Paclitaxel Ebewe6mgceiling Rs 5,823.23 Paclitaxelebewe150mgceiling Rs 25,196.71 Paclitaxelebewe100mgceiling Rs 18,325.68 Paclitaxelebewe300mgceiling Rs 41,977.21 Paclitaxelebewe30mgceiling Rs 5,823.23 Sandostatin LAR20mgceiling Rs 171,145.26 Sandostatin LAR30mgceiling Rs 237,754.57 Sandostatin LAR10mgceiling Rs 131,798.95

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

ceilings with an approval date

not revised in 2+ years

2024

oldest approval year

20241

20267

Longest without revision

Sandostatin LAR 10mgRs 131,798.95 · approved 01 Jul, 2024

Top molecules by brand count

Calcium15 brands

Calcium Carbonate11 brands

Ascorbic Acid9 brands

Eye6 brands

Cholecalciferol6 brands

Pyridoxine5 brands

Pseudoephedrine4 brands

Chloramphenicol3 brands

Gentamicin3 brands

Pyrazinamide3 brands

Therapeutic classes

Conditions treated

Price band (DRAP official ceilings)

Registered products priced by source

DRAP-official8 products · Rs 5,823.23 – Rs 1,011,438.15

DVAGO3 products · Rs 3,300 – Rs 3,410.59

Servaid4 products · Rs 36.3 – Rs 1,655.1

Median across source: Rs 3,355.29

Regulatory record

2 alerts in the DRAP feed we track.

121. Rapid Alert- Falsified SIMULECT (Basiliximab) for injection identified in the WHO Afr

2025-12-10

Safety Alert of Risk of severe cutaneous adverse reactions with Cefotaxime

2025-04-07

Competitive set

Companies whose registered portfolio overlaps most with this one.

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.34 shared molecules

Atco Pharma International (Pvt) Ltd30 shared molecules

VALOR PHARMACEUTICALS30 shared molecules

Genix Pharma Private Limited27 shared molecules

GLOBAL BRANDS DISTRIBUTORS27 shared molecules

Wilshire Laboratories (Private) Limited27 shared molecules

Albro Pharmaceuticals26 shared molecules

IRZA PHARMA (PVT) LTD.25 shared molecules

NEUTRO PHARMA (PVT) LTD.24 shared molecules

REMINGTON PHARMACEUTICAL INDUSTRIES (PVT) LTD.24 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 156 molecules not in this portfolio

Atco Pharma International (Pvt) Ltd holds 231 molecules not in this portfolio

VALOR PHARMACEUTICALS holds 160 molecules not in this portfolio

Get the full profile for NOVARTIS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included